zanidatamab

Home
Ligands
zanidatamab

GtoPdb Ligand ID: 13627

Synonyms: zanidatamab-hrii | Ziihera® | ZW-25 | ZW25

zanidatamab is an approved drug (DA (2024))

Comment: Zanidatamab (ZW25) is an anti-ERBB2 (HER2) monoclonal antibody [3]. It is biparatopic, meaning that it interacts with two independent extracellular epitopes on the ERBB2 receptor. Antibody binding induces ERBB2 internalisation, as well as CDC, ADCC and ADCP. The two epitopes are those bound by trastuzumab (ECD4) and pertuzumab (ECD2). Zanidatamab was designed to treat ERBB2 over-expressing advanced solid tumours, in particular types other than breast cancer [4].

Summary
Biological activity
Clinical data
References

Bioactivity Comments
From patent US10000576 approximate binding affinities (Kd) for the trastuzumab epitope and pertuzumab epitope arms of zanidatamab are 0.3 nM and ~7 nM respectively [3].

Bioactivity Comments

From patent US10000576 approximate binding affinities (Kd) for the trastuzumab epitope and pertuzumab epitope arms of zanidatamab are 0.3 nM and ~7 nM respectively [3].